DaVita Inc. (NYSE:DVA) Shares Sold by Amalgamated Bank

Amalgamated Bank cut its position in DaVita Inc. (NYSE:DVA - Free Report) by 42.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,032 shares of the company's stock after selling 7,287 shares during the period. Amalgamated Bank's holdings in DaVita were worth $1,645,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in DVA. Harvard Management Co. Inc. acquired a new stake in shares of DaVita in the second quarter worth approximately $55,115,000. Lazard Asset Management LLC boosted its stake in DaVita by 147.3% during the first quarter. Lazard Asset Management LLC now owns 256,872 shares of the company's stock worth $35,460,000 after buying an additional 153,008 shares during the last quarter. Jupiter Asset Management Ltd. boosted its stake in DaVita by 146.7% during the first quarter. Jupiter Asset Management Ltd. now owns 187,177 shares of the company's stock worth $25,840,000 after buying an additional 111,311 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in DaVita during the second quarter worth $9,615,000. Finally, International Assets Investment Management LLC acquired a new position in DaVita during the third quarter worth $10,346,000. 90.12% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have weighed in on DVA shares. Bank of America boosted their price objective on DaVita from $139.00 to $145.00 and gave the stock an "underperform" rating in a research note on Wednesday, August 7th. UBS Group boosted their price objective on DaVita from $169.00 to $175.00 and gave the stock a "buy" rating in a research note on Thursday, August 8th. Truist Financial boosted their price objective on DaVita from $165.00 to $175.00 and gave the stock a "hold" rating in a research note on Monday, October 7th. TD Cowen upped their price target on DaVita from $139.00 to $150.00 and gave the company a "hold" rating in a research note on Wednesday, July 24th. Finally, Barclays upped their price target on DaVita from $150.00 to $164.00 and gave the company an "equal weight" rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $161.80.

DaVita Trading Up 0.3 %

DVA traded up $0.45 during mid-day trading on Wednesday, hitting $158.49. 242,771 shares of the stock were exchanged, compared to its average volume of 817,063. The firm's fifty day moving average is $157.34 and its two-hundred day moving average is $147.23. DaVita Inc. has a 1-year low of $89.33 and a 1-year high of $168.50. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. The company has a market cap of $13.00 billion, a PE ratio of 17.02, a PEG ratio of 0.89 and a beta of 0.89.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company had revenue of $3.26 billion for the quarter, compared to analysts' expectations of $3.25 billion. During the same quarter last year, the company earned $2.85 EPS. DaVita's revenue for the quarter was up 4.6% compared to the same quarter last year. Equities analysts forecast that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Michael David Staffieri sold 9,539 shares of the stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $150.03, for a total value of $1,431,136.17. Following the transaction, the chief operating officer now owns 241,945 shares in the company, valued at approximately $36,299,008.35. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, COO Michael David Staffieri sold 9,539 shares of the firm's stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the transaction, the chief operating officer now owns 241,945 shares in the company, valued at $36,299,008.35. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Javier Rodriguez sold 50,000 shares of the firm's stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the transaction, the chief executive officer now owns 837,835 shares in the company, valued at $138,284,666.75. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 165,625 shares of company stock worth $26,238,297. 2.00% of the stock is currently owned by insiders.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.